Last reviewed · How we verify
PVRV and pERIG Favirab®
PVRV and pERIG Favirab® is a Monoclonal antibody immunoglobulin (rabies-specific) Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Post-exposure prophylaxis of rabies following potential rabies virus exposure. Also known as: VERORAB®; pERIG Favirab®.
PVRV and pERIG Favirab® are rabies immunoglobulins that provide passive post-exposure prophylaxis by neutralizing rabies virus through direct antibody binding.
PVRV and pERIG Favirab® are rabies immunoglobulins that provide passive post-exposure prophylaxis by neutralizing rabies virus through direct antibody binding. Used for Post-exposure prophylaxis of rabies following potential rabies virus exposure.
At a glance
| Generic name | PVRV and pERIG Favirab® |
|---|---|
| Also known as | VERORAB®; pERIG Favirab® |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Monoclonal antibody immunoglobulin (rabies-specific) |
| Target | Rabies virus glycoprotein |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Favirab® is a monoclonal antibody-based rabies immunoglobulin designed to neutralize rabies virus particles and prevent viral entry into cells. It is administered as part of post-exposure prophylaxis (PEP) regimens following potential rabies exposure, working synergistically with rabies vaccine to provide rapid passive immunity while the vaccine generates active immunity. PVRV and pERIG refer to different formulations or manufacturing processes for this rabies immunoglobulin product.
Approved indications
- Post-exposure prophylaxis of rabies following potential rabies virus exposure
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Headache
Key clinical trials
- Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PVRV and pERIG Favirab® CI brief — competitive landscape report
- PVRV and pERIG Favirab® updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about PVRV and pERIG Favirab®
What is PVRV and pERIG Favirab®?
How does PVRV and pERIG Favirab® work?
What is PVRV and pERIG Favirab® used for?
Who makes PVRV and pERIG Favirab®?
Is PVRV and pERIG Favirab® also known as anything else?
What drug class is PVRV and pERIG Favirab® in?
What development phase is PVRV and pERIG Favirab® in?
What are the side effects of PVRV and pERIG Favirab®?
What does PVRV and pERIG Favirab® target?
Related
- Drug class: All Monoclonal antibody immunoglobulin (rabies-specific) drugs
- Target: All drugs targeting Rabies virus glycoprotein
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for Post-exposure prophylaxis of rabies following potential rabies virus exposure
- Also known as: VERORAB®; pERIG Favirab®
- Compare: PVRV and pERIG Favirab® vs similar drugs
- Pricing: PVRV and pERIG Favirab® cost, discount & access